2 results for "rare-disease"
Astellas reenters clinic with next-gen XLMTM gene therapy after fatal trial. Meanwhile, Intellia's CRISPR cuts swelling attacks by 87% in Phase 3. The new AAV8
A revolutionary clinical trial design approach could make personalized CRISPR therapies economically viable for thousands with rare genetic diseases. Precision
